Biopharmaceutical Firm Presents Major Life Science Partnership Update

Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical firm dedicated to developing innovative therapeutics for autoimmune, inflammatory, and fibrotic diseases, has provided an update on its collaboration with Strand Life Sciences ("Strand"), a prominent bioinformatics specialist. This partnership is focused on enhancing precision medicine for ulcerative colitis (UC) therapy through the integration of cutting-edge expertise and bioinformatics tools. $Palisades Goldcorp Ltd (PALI.CA)$